2025-10-20 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the data you provided, formatted for a report and incorporating key insights.

## Merck & Co Inc (MRK) Analysis

**Ticker:** MRK
**Company Name:** Merck & Co Inc
**Description:** Merck & Co. Inc. is a global pharmaceutical company that develops and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** 0.25
*   **VOO Cumulative Return:** 97.05
*   **Absolute Divergence:** -96.8
*   **Relative Divergence:** 5.6 (meaning the divergence is near the lower end of its historical range).

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative divergence suggests this underperformance is near the extreme end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta    | Cap(B)  |
|------------|-----------|-------|----------|---------|---------|
| 2015-2017  | 1.0%      | 68.5% | -28.0%   | 0.0     | 134.1   |
| 2016-2018  | 36.0%     | 69.8% | 21.0%    | -0.0    | 182.1   |
| 2017-2019  | 40.0%     | 69.8% | 18.0%    | 0.3     | 216.8   |
| 2018-2020  | 16.0%     | 79.6% | -8.0%    | 0.3     | 195.0   |
| 2019-2021  | 2.0%      | 79.6% | -44.0%   | 0.7     | 191.4   |
| 2020-2022  | 15.0%     | 79.6% | 16.0%    | 0.7     | 277.1   |
| 2021-2023  | 33.0%     | 79.6% | 31.0%    | 0.3     | 272.3   |
| 2022-2024  | -4.0%     | 79.6% | -25.0%   | 0.2     | 248.5   |
| 2023-2025  | -49.0%    | 71.5% | -111.0%  | 1.6     | 211.8   |

*   **CAGR:** Fluctuates significantly, showing periods of strong growth and sharp decline. The recent period (2023-2025) is particularly concerning.
*   **MDD:** High Maximum Drawdown values suggest significant volatility and potential for losses.
*   **Alpha:** Varies widely, indicating periods of outperformance and underperformance relative to the market. The most recent period shows a very negative alpha.
*   **Beta:** Generally low (close to 0), indicating MRK's price movements have been less sensitive to broader market movements. However, the recent beta of 1.6 suggests increased market sensitivity recently.
*   **Cap(B):** Market capitalization fluctuates over the years.

**Analysis:** The historical data reveals that Merck's performance has been inconsistent, with periods of strong growth followed by sharp declines. The negative Alpha in recent years suggests significant underperformance compared to the market. The increasing Beta could indicate a recent shift towards higher market sensitivity, which can be concerning during market downturns.

### 2. Recent Stock Price Movement

*   **Current Price:** 84.79
*   **Last Market Close:** Price: 84.79, Previous Close: 83.92, Change: 1.04
*   **5-Day Moving Average:** 84.644
*   **20-Day Moving Average:** 84.3775
*   **60-Day Moving Average:** 83.3799

**Analysis:** The stock price is trading above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend. The positive change from the previous close supports this.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 63.26 (Approaching overbought territory)
*   **PPO:** -0.2879
*   **Hybrid Signal:** Buy 100% of cash (35 shares - Very Safe - MRI:0.90), Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent (20-Day) Relative Divergence Change:** -3.6 (Short-term decline)
*   **Expected Return:** -121.3% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests low investment risk, while the Hybrid Signal recommends a buy strategy with a small monthly investment.
*   The RSI is approaching overbought levels, suggesting the stock may be due for a pullback.
*   The PPO is negative, but close to zero, indicating that the recent price increase is not yet a strong momentum signal.
*   The negative change in relative divergence aligns with recent underperformance compared to the S&P 500.
*   The very low expected return suggests a pessimistic outlook for future relative performance.
*   The recent price change (1.04) is relatively significant, but may not be large enough to warrant a major change in investment strategy.

### 4. Recent News & Significant Events

*   **Positive Clinical Trial Results:** Multiple headlines highlight positive clinical trial results for KEYTRUDA in combination with other therapies for various cancers (ovarian, bladder, endometrial).  Raludotatug Deruxtecan also showed promise in ovarian cancer.
*   **Potential Sales Decline:** One headline warns of potentially declining Gardasil sales in Q3, which could affect MRK's top line.

**Analysis:** Recent news is mixed.  Positive clinical trial results are generally positive for stock price, but concerns about Gardasil sales could create negative pressure.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.00)
*   **Opinions:** 25
*   **Target Price:** Average: 101.84, High: 137.00, Low: 82.00

**Analysis:**  Analysts generally have a positive outlook on the stock, with a "Buy" consensus and a significant average target price above the current price.  However, the low target price is below the current price, showing differing opinions from analysts.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-08-05   | 1.76 | 15.81 B$   |
| 2025-05-02   | 2.01 | 15.53 B$   |
| 2024-11-06   | 1.25 | 16.66 B$   |
| 2024-08-05   | 2.15 | 16.11 B$   |
| 2025-08-05   | 2.15 | 16.11 B$   |

**Analysis:** The EPS has fluctuated, with a noticeable dip in the most recent quarter. Revenue has also shown some variability, but has been relatively stable over the past few quarters. The most recent EPS data may be concerning, as it represents a significant drop from previous quarters.

### 6. Financial Information

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $15.81B  | 77.50%        |
| 2025-03-31   | $15.53B  | 77.98%        |
| 2024-12-31   | $15.62B  | 75.50%        |
| 2024-09-30   | $16.66B  | 75.51%        |
| 2024-06-30   | $16.11B  | 76.76%        |

| Quarter      | Equity   | ROE       |
|--------------|----------|-----------|
| 2025-06-30   | $48.99B  | 9.04%     |
| 2025-03-31   | $48.34B  | 10.51%    |
| 2024-12-31   | $46.31B  | 8.08%     |
| 2024-09-30   | $44.50B  | 7.09%     |
| 2024-06-30   | $43.58B  | 12.52%    |

**Analysis:**

*   **Revenue:** Relatively stable with some fluctuations.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Generally increasing, suggesting growth in the company's net worth.
*   **ROE:** Varies, indicating fluctuations in the company's ability to generate profits from equity. The most recent ROE is lower than in previous quarters.

### 7. Summary and Conclusion

Merck & Co. Inc. (MRK) presents a mixed investment picture. While analyst opinions are generally positive, with an average target price above the current level, the company has significantly underperformed the S&P 500 recently. Positive news in the clinical trial space contrasts with the potential for declining Gardasil sales.

*   **Positives:**
    *   Strong profit margins.
    *   Positive clinical trial results.
    *   "Buy" consensus from analysts.
*   **Negatives:**
    *   Significant underperformance compared to the S&P 500.
    *   Negative expected return relative to the S&P 500.
    *   Potential for declining Gardasil sales.
    *   Recent decline in EPS and ROE.

**Overall Recommendation:** Given the recent underperformance, negative expected return, and concerning EPS trends, a cautious approach is warranted. While analyst ratings are positive, investors should carefully weigh the risks before making any investment decisions. Monitoring future earnings reports and sales data will be critical to understanding the company's trajectory.
